Fluidising effect of resorcylidene aminoguanidine on sarcolemmal membranes in streptozotocin-diabetic rats: Blunted adaptation of diabetic myocardium to Ca2+ overload

Journal of Physiology and Pharmacology

Volumn 53, Issue 4 II, 2002, Pages 727-739

  Waczulíková, Iveta ^a   Ziegelhoffer A ^b   Orszaghova Z ^a   Carsky J ^a  

^a Physics and Informatics   (Slovakia)

^b INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

DPH fluorescence anisotropy; Glycation; Heart sarcolemma; Membrane fluidity; Resorcylidene aminoguanidine

Indexed keywords

AMINOGUANIDINE; CALCIUM; RESORCYLIDENE AMINOGUANIDINE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG SYNTHESIS; GLYCATION; GLYCOSYLATION; HEART MUSCLE; HEART MUSCLE FIBER MEMBRANE; MALE; MEMBRANE FLUIDITY; NONHUMAN; RAT; STREPTOZOCIN DIABETES;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; BLOOD GLUCOSE; CALCIUM; DIABETES MELLITUS, EXPERIMENTAL; EXTRACELLULAR SPACE; FRUCTOSAMINE; GLYCOSYLATION; GUANIDINES; HEART; MALE; MEMBRANE FLUIDITY; MYOCARDIUM; RATS; RATS, WISTAR; SARCOLEMMA;

EID: 0036908253     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Lyons TJ. Glycation and oxidation - A role in the pathogenesis of atherosclerosis. Am J Cardiol 1993; 71: B26-B31.
2. Wolff SP. Free radicals and glycation theory. In: Ikan R, ed. The Maillard Reaction: Consequences for the Chemical and Life Sciences. New York: John Wiley Sons Ltd, 1996:73-88.
3. Brownlee M. Glycosylation products as toxic mediators of diabetic complications. Annu Rev Med 1991; 42: 159-166.
4. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992; 15: 1835-1843.
5. Watala C, Gwozdzinski K, Malek M. Direct evidence for the alterations in protein structure and conformation upon in vitro nonenzymatic glycosylation. Int J Biochem 1992; 24: 1295-1302.
6. Ziegelhoffer A, Ravingerová T, Styk J, Seboková J, Waczulíková I, Breier A, Dzurba A, Volkovová K, Čársky J, Turecký L. Mechanisms that may be involved in calcium tolerance of the diabetic heart. Mol Cell Biochem 1997; 176: 191-198.
7. Ziegelhoffer A, Ravingerová T, Styk J, Tribulová N, Volkovová K, Seboková J, Breier A. Diabetic cardiomyopathy in rats: Biochemical mechanisms of increased tolerance to calcium. Diabetes Res Clin Pract 1996; 31: S93-S103.
8. Ziegelhoffer A, Ravingerová T, Styk J, Dzurba A, Volkovová K, Čársky J. Waczulíková I. Hearts with diabetic cardiomyopathy: Adaptation to calcium overload. Exp Clin Cardiol 1998; 3: 158-161.
9. Ravingerova T, Neckar J, Kolar F, Stetka R, Volkovova K, Ziegelhoffer A, Styk J. Ventricular arrhythmias following coronary artery occlusion in rats: Is the diabetic heart less or more sensitive to ischaemia? Basic Res Cardiol 2001; 96: 160-168.
10. Ziegelhoffer A, Styk J, Ravingerová T, Seboková J, Volkovová K, Waczulíková I, Čársky J., Džurba A, Dočolomanský P. Prevention of processes coupled with free radical formation prevents also the development of Ca-resistance in the diabetic Heart. Life Sci 1999; 65: 1999-2001.
11. Čársky J., Lazarova M, Beño A. Study of resorcylidene aminoguanidine. I. Spectral and acid-basic properties of the onium compounds. Acta F R N Univ Comen Chimia 1978; 26: 89-102.
12. Jakuś V, Hrnčiarová M, Čársky J, Krahulec B, Rietbrock N. Inhibition of non-enzymatic glycation and lipid peroxidation by drugs with antioxidant activity. Life Sci 1999; 65: 1991-1994.
13. Onuska KD, Taylor NJ, Čársky J. Crystal and molecular structure of β-resorcylidene aminoguanidine copper (II) complex. J Chem Crystallogr 1996; 26: 841-846.
14. Waczulíková I, Śikurová L, Čársky J, Strbová L, Krahulec B. Decreased fluidity of isolated erythrocyte membranes in type 1 and type 2 diabetes. The effect of resorcylidene aminoguanidine. Gen Physiol Biophys 2000; 19: 381-392.
15. Waczulíková I, Śikurová L, Čársky J. Fluidity gradient alterations in erythrocyte membranes in diabetics. The effect of resorcylidene aminoguanidine. Bioelectrochemistry 2001; 53.
16. 2+ overload. Diabetes Res Clin Pract 1996; 31: S105-S115.
17. Tinder P. Determination of blood glucose using 4-aminophenazone as oxygen acceptor. J Clin Path 1969; 22: 246-253.
18. Watson D. A simple method for determination of serum cholesterol. Clin Chim Acta 1960; 5: 613-615.
19. Burrin JM, Worth R, Ashworth AA, Curtis S, Alberti KGMM. Automated colorimetric estimation of glycosylated hemoglobin. Clin Chim Acta 1980; 106: 45-50.
20. Vrbjar N, Soos J, Ziegelhoffer A. Secondary structure of heart sarcolemmal proteins during interaction with metallic cofactors of (Na,K)-ATPase. Gen Physiol Biophys 1984; 3: 317-325.
21. Johnson RN, Metcalf PA, Baker JK. Fructosamine: A new approach to estimation of serum glycosyl protein. An index of diabetic control. Clin Chim Acta 1983; 127: 87-95.
22. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
23. Plasek J, Jarolim P. Interaction of the Fluorescent Probe 1,6-Diphenyl-1,3,5-Hexatriene with Biomembranes. Gen Physiol Biophys 1987; 6: 425-437.
24. Śikurová L, Mateasik A, Ruttkay-Nedecký G. Lipid packing changes in erythrocyte membranes induced by receptor destroying enzyme. Acta Physica Universitatis Comenianae 1998; 39: 111-115.
25. Van der Meer BW, Van Hoeven RP, Van Blitterswijk WJ. Steady-state fluorescence polarization data in membranes. Resolution into physical parameters by an extended Perrin equation for restricted rotation of fluorophores. Biochim Biophys Acta 1986; 854: 38-44.
26. Mateo CR, Lillo MP, Gonzalezrodriguez J, Acuna AU. Molecular order and fluidity of the plasma membrane of human platelets from time-resolved fluorescence depolarization. Eur Biophys J 1991; 20: 41-52.
27. Shinitzky M. Membrane fluidity and receptor function. In: Kates M, Manson LA, eds. Biomembranes: Membrane Fluidity. New York and London: Plenum Press, 1984; 585-601.
28. Dhalla NS, Pierce GN, Innes IR, Beamish RE. Pathogenesis of cardiac dysfunction in diabetes mellitus. Can J Cardiol 1985; 1: 263-281.
29. Śikurová L, Dérerová J, Kvasnička P, Waczulíková I, Čársky J, Uličná O. Resorcylidene aminoguanidine improves the pathologically reduced fluidity of erythrocyte membranes in diabetes mellitus. Pharmazie 2000; 55: 700-701.
30. Augustyniak K, Zavodnik I, Palecz D., Szosland K, Bryszewska M. The effect of oxidizing agents and diabetes mellitus on the human red blood cell membrane potential. Clin Biochem 1996; 29: 283-286.
31. Waczulíková I, Śikurová L, Bryszewska M, Rȩkawiecka K, Čársky J. Impaired erythrocyte transmembrane potential in diabetes mellitus and its possible improvement by resorcylidene aminoguanidine. Bioelectrochemistry 2000; 52: 251-256.
32. Gotzsche O. Myocardial calcium uptake and catecholamine sensitivity in experimental diabetes. In: Nagano M, Dhalla NS, eds. The Diabetic Heart. New York: Raven Press, 1991; 199-207.
33. 2+ metabolism. Circ Res 1988; 62: 931-940.
34. Ziegelhoffer A, Kjeldsen K, Bundgaard H, Breier A, Vrbjar N, Dzurba A. Na,K-ATPase in the myocardium: Molecular principles, functional and clinical aspects. Gen Physiol Biophys 2000; 19: 9-47.
35. Pierce GN, Ramniwan B, Meng H-P. Cardiac sarcolemmal membrane alterations during the diabetic cardiomyopathy. In: Nagano M, Dhalla NS, eds. The Diabetic Heart. New York: Raven Press, 1991; 229-36.
36. + ATPase by oxyradical generating sysrems. Mol Cell Biochem 1995; 145: 139-144.